Brief: Chromadex Says Results From Phase II Clinical Study Show Promising Effects Of NR Supplementation For People With Peripheral Artery Disease
24/06/2024 15:38
June 24 (Reuters) - Chromadex Corp CDXC.O :
* CHROMADEX CORP: RESULTS FROM PHASE II CLINICAL STUDY SHOW
PROMISING EFFECTS OF NR SUPPLEMENTATION FOR PEOPLE WITH
PERIPHERAL ARTERY DISEASE (PAD)
Source text for Eikon: ID:nBw5p1mm8a
Further company coverage: CDXC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Niagen Bioscience
See all newsAs weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Niagen Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary
Niagen Bioscience Q2 net sales fall, missing estimates
Niagen Bioscience Inc expected to post earnings of 2 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce